Visteon Announces $300M Share Repurchase Authorization Expiring December 31, 2026

Visteon Corporation (NASDAQ:VC) today announced that its board of directors has authorized a share repurchase program of $300 million of common stock expiring December 31, 2026. Visteon expects to fund the

Visteon Corporation (NASDAQ:VC) today announced that its board of directors has authorized a share repurchase program of $300 million of common stock expiring December 31, 2026. Visteon expects to fund the repurchases through excess cash on hand and future cash flow generation.
 

“We are pleased to announce this new share repurchase program, further underscoring our commitment to driving value for our shareholders,” said Sachin Lawande, Visteon president and CEO. “This authorization demonstrates our board’s confidence in Visteon’s strategic growth plan as we deliver digital, software-defined, and electric product solutions that align with key trends in the industry.”

Shares may be repurchased from time to time in open market transactions or in privately negotiated transactions depending on market and economic conditions, share price, trading volume, alternative uses of capital and other factors. Such purchases will be made in accordance with applicable U.S. securities laws and regulations.

Total
0
Shares
Related Posts
Read More

Puma Biotechnology Announced Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress, currently taking place in Paris, France.

PBYI